Largest Phase III trial of novel treatment for hypertension shows promising results

image via Medical Xpress - medical research advances and health news

May 26, 2025, 12:37 PM

• •Lorundrostat, an aldosterone synthase inhibitor, demonstrated significant and sustained reductions in systolic blood pressure in the Launch-HTN trial.
• •The trial, the largest Phase III study of its kind, showed lorundrostat's safety and effectiveness in a diverse patient population with uncontrolled or resistant hypertension.
• •The study, led by Dr. Manish Saxena, highlights the need for novel hypertension treatments as over 40% of adults worldwide don't reach their blood pressure goals.
• •Lorundrostat, by inhibiting the enzyme responsible for aldosterone production, offers a potential new treatment option for millions with hypertension.

The Launch-HTN trial results, presented at the European Meeting on Hypertension and Cardiovascular Protection, reveal that lorundrostat, an aldosterone synthase inhibitor, is a safe and effective treatment for uncontrolled or resistant hypertension. This Phase III trial, led by Dr. Manish Saxena, demonstrated consistent blood pressure reductions across a diverse patient population. The study's findings mark a significant step towards providing a targeted treatment for millions affected by hypertension. Lorundrostat, which works by inhibiting aldosterone production, could become a novel treatment option for individuals worldwide.

Read original article